Sulfur In Substituent Q Patents (Class 564/162)
-
Publication number: 20100036164Abstract: Preparation of armodafinil crystalline Form I. Also provided is armodafinil having about 30% or more by weight of particles with sizes greater than about 250 ?m, and about 70% or less by weight of particles having sizes less than about 250 ?m, wherein of the particles having sizes less than about 250 ?m, about 50% of them have diameters less than about 50 ?m.Type: ApplicationFiled: August 5, 2009Publication date: February 11, 2010Inventors: Srinivas Areveli, Radha Krishna Singamsetty, Satish Kumar Vujjni, Vijaya Kumar Adla, Sreenadha Charyulu Kandala, Ganesh Varanasi, Subbareddy Peddireddy, Mohammed Azeezulla Baig
-
Publication number: 20100022653Abstract: The invention relates to a polymorphic form of (?)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 ?, and a process for the preparation thereof.Type: ApplicationFiled: July 22, 2009Publication date: January 28, 2010Applicant: Cephalon FranceInventors: Olivier NECKEBROCK, Laurent COURVOISIER, Stéphanie GRAF, Gilles SERRURE, Gérard Francois COQUEREL, Sébastien ROSE, Christine BESSELIEVRE, Franck Patrick MALLET, Adriaan Jan VAN LANGEVELDE
-
Publication number: 20090317481Abstract: The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns.Type: ApplicationFiled: September 2, 2009Publication date: December 24, 2009Applicant: CEPHALON, INC.Inventors: Moshe Bentolila, Aldo Shusterman, Moshe Arkin, Joseph Kaspi
-
Publication number: 20090312575Abstract: Disclosed is a process for preparing anti-inflammatory compound nepafenac comprising preparing a compound of formula (V) wherein a N-halosuccinimide is used as the halogenating agent, followed by desulfurization using Raney Nickel. Also disclosed is a polymorphic form B of 2-amino-3-benzoyl-?-(methylthio)-benzeneacetamide (i.e.Type: ApplicationFiled: June 12, 2009Publication date: December 17, 2009Applicant: Medichem, S.A.Inventors: Gabriel Tojo Suarez, Ana Gavalda Escude
-
Patent number: 7632971Abstract: The present invention provides a method of crystallization of bicalutamide comprising adding an acetone solution containing bicalutamide to water; crystals of bicalutamide wherein particle size distribution of the crystals is 1 to 10 ?m of Dp10, 10 to 25 ?m of Dp50 and 25 to 100 ?m of Dp90, and the crystals are obtainable by the method described above; and crystals of bicalutamide, wherein particle size distribution of the crystals is 1 to 3 ?m of Dp10, 2 to 5 ?m of Dp50 and 5 to 15 ?m of Dp90.Type: GrantFiled: July 13, 2005Date of Patent: December 15, 2009Assignee: Sumitomo Chemical Company, LimitedInventors: Tadashi Katsura, Tadashi Mizuno, Nobushige Itaya
-
Patent number: 7629493Abstract: The invention relates to a process for the crystallization of the compounds of the formula (I) or acid-addition salts thereof, in which R1, R2 and R3 have the meaning indicated in Claim 1.Type: GrantFiled: April 10, 2004Date of Patent: December 8, 2009Assignee: Merck Patent GmbHInventors: Michael Kirschbaum, Ekkehard Bartmann, Dieter Bensinger, Alexander Haas, Ricky Lippert
-
Publication number: 20090292025Abstract: The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms, and pharmaceutical formulation.Type: ApplicationFiled: June 8, 2009Publication date: November 26, 2009Applicant: Teva Pharmaceutical Industries Ltd.Inventors: Viviana Braude, Rinat Moshkovits-Kaptsan, Sigalit Levi
-
Patent number: 7622611Abstract: Pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings stated in the claims, are suitable, for example, as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.Type: GrantFiled: January 11, 2008Date of Patent: November 24, 2009Assignee: Sanofi-Aventis Deutschland GmbHInventor: Heinz-Werner Kleemann
-
Patent number: 7622612Abstract: The present invention relates to tricyclic colchicine derivatives represented by the formulas (I) or (II), pharmaceutically acceptable salts thereof, and a method for providing an immuno-suppressive or immuno-modulating effect, an anti-proliferative effect, an anti-inflammatory effect or a method for treating cancer comprising administering to a patient an effective amount of one or more colchicine derivatives:Type: GrantFiled: July 10, 2006Date of Patent: November 24, 2009Assignees: Chemtech Research Incorporation, KT & G CorporationInventors: Dong Jo Chang, Eun Young Yoon, Gun Bong Lee, Soon Ok Kim, Wan Joo Kim
-
Publication number: 20090281192Abstract: The invention relates to a polymorphic form of (?)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 12.38, 8.58, 7.34, 5.00 and 4.09 ?, and a process for the preparation thereof.Type: ApplicationFiled: July 22, 2009Publication date: November 12, 2009Applicant: Cephalon FranceInventors: Olivier NECKEBROCK, Laurent COURVOISIER, Stéphanie GRAF, Gilles SERRURE, Gérard Francois COQUEREL, Sébastien ROSE, Christine BESSELIEVRE, Franck Patrick MALLET, Adriaan Jan VAN LAGEVELDE
-
Publication number: 20090281193Abstract: The invention relates to a polymorphic form of (?)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 9.45, 7.15, 5.13, 4.15 and 3.67 ?, and a process for the preparation thereof.Type: ApplicationFiled: July 22, 2009Publication date: November 12, 2009Applicant: Cephalon FranceInventors: Olivier Neckebrock, Laurent Courvoisier, Stephanie Graf, Gilles Serrure, Gérard François Coquerel, Sébastien Rose, Christine Besselievre, Franck Patrick Mallet, Adriaan Jan Van Langevelde
-
Publication number: 20090270510Abstract: The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.Type: ApplicationFiled: December 21, 2005Publication date: October 29, 2009Applicant: GLAXO GROUP LIMITEDInventors: Daniel Marcus Bradley, Clive Leslie Branch, Wai Ngor Chan, Steven Coulton, Martin Leonard Gilpin, Andrew Jonathan Harris, Justine Yeun Quai Lai, Jacqueline Anne Macritchie, Howard Robert Marshall, David John Nash, Roderick Alan Porter, Simone Spada, Kevin Michael Thewlis, Simon Edward Ward
-
Patent number: 7595344Abstract: Disclosed are sulphones which modulate the action of gamma-secretase. The compounds are useful in the treatment or prevention of Alzheimer's disease.Type: GrantFiled: May 6, 2008Date of Patent: September 29, 2009Assignee: Merck Sharp & Dohme LimitedInventors: Jose Luis Castro Pineiro, Ian Churcher, Kevin Dinnell, Timothy Harrison, Sonia Kerrad, Alan John Nadin, Paul Joseph Oakley, Andrew Pate Owens, Duncan Edward Shaw, Martin Richard Teall, Susannah William, Brian John Williams
-
Publication number: 20090239829Abstract: There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R1, R2, n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors of zinc metalloproteinases.Type: ApplicationFiled: July 25, 2007Publication date: September 24, 2009Applicant: BRACCO IMAGING SPAInventors: Armando Rossello, Elisabetta Orlandini, Aldo Balsamo, Laura Panelli, Elisa Nuti
-
Patent number: 7566805Abstract: Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.Type: GrantFiled: September 4, 2004Date of Patent: July 28, 2009Assignee: Cephalon, Inc.Inventors: Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
-
Publication number: 20090178513Abstract: Provided is a novel extractant for palladium capable of improving an extraction rate compared to the conventional extractant, DHS, and also capable of back-extracting palladium using an ammonia solution, and a method of separating and recovering palladium using the novel extractant.Type: ApplicationFiled: January 9, 2009Publication date: July 16, 2009Applicant: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Hirokazu Narita, Mikiya Tanaka, Ken Tamura
-
Publication number: 20090176853Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).Type: ApplicationFiled: December 4, 2008Publication date: July 9, 2009Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
-
Patent number: 7553646Abstract: The present invention provides novel methods for the synthesis of racemic and enantiomers of modafinil via microbial oxidation-amidation transformation. The methods include the successive oxidation-amidation of benzhydrylsulfanyl carboxylic acid to produce racemic and enantiomers of modafinil using at least one microorganism of yeast, bacteria, or fungus. Also disclosed are pharmaceutical compositions of racemic and enantiomers of modafinil along with their use in the treatment of diseases, including attention deficit hyperactivity disorder and drug addiction.Type: GrantFiled: July 27, 2006Date of Patent: June 30, 2009Assignee: University of Iowa Research FoundationInventors: Horacio F. Olivo, Antonio Victor Osorio-Lozada
-
Patent number: 7550474Abstract: Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.Type: GrantFiled: April 1, 2004Date of Patent: June 23, 2009Assignee: Johnson & Johnson Pharmaceuticals Research & Development, L.L.C.Inventors: Kevin D. Kreutter, Lily Lee, Tianbao Lu, Venkatraman Mohan, Sharmila Patel, Hui Huang, Guozhang Xu, Mark Fitzgerald
-
Publication number: 20090143445Abstract: This invention provides the compound having the structure wherein n is 1-10; X is C—R11 or N, wherein R11 is H, OH, SH, F, Cl, SO2R7, NO2, trifluoromethyl, methoxy, or CO—R7, wherein R7 is alkyl, alkenyl, alkynyl, C3-C8 cycloalkyl, or aryl; Z is R2 is H or NR3R4, wherein R3 and R4 are each independently H, C1-C6 alkyl, or C3-C8 cycloalkyl; R5 is OH or SH; and R6, R12, R13, and R14 are each independently H, OH, SH, F, Cl, SO2R15, NO2, trifluoromethyl, methoxy, or CO—R15 wherein R15 is alkyl, alkenyl, alkynyl, C3-C8 cycloalkyl, or aryl, or a salt of the compound, which is useful in the treatment of tumors.Type: ApplicationFiled: October 1, 2008Publication date: June 4, 2009Inventors: John S. Kovach, Francis Johnson
-
Patent number: 7541493Abstract: The invention relates to a process for preparing modafinil having a defined granulometry which comprises the steps of: a) preparing a solution of DMSAM; b) contacting the solution obtained with NH3 at a predetermined temperature and a predetermined stirring; and c) isolating the modafinil formed, wherein said temperature and said stirring are predetermined in order to obtain said defined granulometry.Type: GrantFiled: May 5, 2004Date of Patent: June 2, 2009Assignee: Cephalon FranceInventor: Sébastien Rose
-
Publication number: 20090137594Abstract: The present invention relates to pentafluorosulphanyl-substituted compounds, methods for their production, medicaments containing such compounds and the use of such compounds for producing medicaments.Type: ApplicationFiled: May 17, 2006Publication date: May 28, 2009Applicant: Gruenenthal GmgHInventors: Robert Frank, Bernd Sundermann, Hans Schick
-
Publication number: 20090118290Abstract: The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and ?-secretase. Also provided are methods of using the derivatives to treat pathological disorders.Type: ApplicationFiled: January 5, 2009Publication date: May 7, 2009Inventors: Lawrence J. Marnett, Jeffery J. Prusakiewicz, Andrew S. Felts, Chuan Ji
-
Publication number: 20090105309Abstract: Compounds of formula (I): and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective ?2-adrenoreceptor agonist is indicated, for example asthma or chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: October 20, 2004Publication date: April 23, 2009Applicant: GLAXO GROUP LIMITEDInventors: Philip Charles Box, Diane Mary Coe, Heather Hobbs
-
Publication number: 20090105346Abstract: The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms of armodafinil, pharmaceutical formulation thereof, and method of treating excessive sleepiness using the formulations of the invention.Type: ApplicationFiled: October 2, 2008Publication date: April 23, 2009Inventor: Alexandr Jegorov
-
Publication number: 20090099264Abstract: The present invention provides compounds of formula I which are inhibitors of cathepsin S and as such are useful in the prevention and treatment of cathepsin S dependent diseases and conditions including, but not limited to, chronic obstructive pulmonary disease (COPD) and pain.Type: ApplicationFiled: May 30, 2006Publication date: April 16, 2009Applicant: MERCK FROSST CANADA LTD.Inventors: Cameron Black, Jacques Yves Gauthier
-
Patent number: 7511175Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.Type: GrantFiled: January 5, 2006Date of Patent: March 31, 2009Assignee: Abbott LaboratoriesInventors: Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Peer B. Jacobson, Michael E. Brune
-
Publication number: 20090082462Abstract: The present application describes deuterium-enriched amodafinil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: September 18, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090082461Abstract: The present application describes deuterium-enriched modafinil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 22, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090076158Abstract: The present application describes deuterium-enriched bicalutamide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: September 5, 2008Publication date: March 19, 2009Applicant: PROTIA, LLCInventor: Anthony W Czarnik
-
Publication number: 20090062284Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl acetamides of Formula (I): wherein Ar, Y, R1, R2, R4, R5, q and x are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder; Parkinson's disease; Alzheimer's disease; attention deficit disorder; attention deficit hyperactivity disorder; depression; or fatigue associated with a neurological disease; as well as the promotion of wakefulness.Type: ApplicationFiled: August 27, 2008Publication date: March 5, 2009Applicant: Cephalon, Inc.Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, Marie-Edith Gourdel, Greg A. Hostetler, Mohamed Iqbal, Brigitte Lesur, Philippe Louvet, Eric Riguet, Dominique Schweizer, Christophe Yue
-
Publication number: 20090054444Abstract: Compounds of Formula (I) wherein R1 is a cycloalkylsulphonyl group, or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.Type: ApplicationFiled: August 9, 2005Publication date: February 26, 2009Inventors: Matthew Colin Thor Fyfe, Vilasben Kanji Shah
-
Publication number: 20090048464Abstract: The invention encompasses processes for obtaining pure armodafinil substantially free of disulfide impurities that is suitable for use on an industrial scale. In particular, a processes for purifying armodafinil from bis(diphenylmethyl)disulfide comprising: dissolving crude armodafinil in ethanol to form a solution; adding a solvent selected from the group consisting of linear or branched C5-C8 alkyl, linear or branched C5-C8 ether, and mixtures thereof to the solution to form a reaction mixture; cooling the reaction mixture; and isolating pure armodafinil from the reaction mixture.Type: ApplicationFiled: August 18, 2008Publication date: February 19, 2009Inventor: Boaz Gome
-
Patent number: 7488844Abstract: The present invention provides a compound of formula I processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.Type: GrantFiled: December 30, 2004Date of Patent: February 10, 2009Assignee: AstraZeneca ABInventors: Eva-Lotte Lindstedt Alstermark, Anna Christina Olsson, Lanna Li
-
Publication number: 20090036704Abstract: A process for preparing 4-pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings indicated in the specification. The compounds of formula I are NHE1 inhibitors and can be employed, for example, for the treatment of cardiovascular disorders.Type: ApplicationFiled: October 9, 2008Publication date: February 5, 2009Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Gerrit Schubert, Heinz-Werner Kleemann
-
Publication number: 20090036420Abstract: The present invention relates to methods of treating CNS disorders with a compound of formula I wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof.Type: ApplicationFiled: July 28, 2008Publication date: February 5, 2009Inventors: Guido Galley, Katrin Groebke Zbinden, Roger Norcross, Henri Stalder
-
Publication number: 20090030232Abstract: The present invention is directed to the labeled compounds, wherein C* is each either 13C and 12C where at least one C* is 13C, each hydrogen of the methylene group is hydrogen or deuterium, the methyl group includes either zero or three deuterium atoms, Q is sulfide, sulfinyl, or sulfone, Z is an aryl group such as 1-naphthyl, substituted 1-naphthyl, 2-naphthyl, substituted 2-naphthyl, or a phenyl group wherein R1, R2, R3, R4 and R5 are each independently either hydrogen, a C1-C4 lower alkyl, a halogen, and an amino group such as NH2, NHR and NRR? where R and R? are each independently either a C1-C4 lower alkyl, a phenyl, and an alkoxy group, and the methyl group can include either zero or three deuterium atoms.Type: ApplicationFiled: July 22, 2008Publication date: January 29, 2009Inventors: Rodolfo A. Martinez, Clifford J. Unkefer, Marc A. Alvarez
-
Publication number: 20090023781Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: ApplicationFiled: December 1, 2005Publication date: January 22, 2009Applicant: Virobay, Inc.Inventor: Eduardo L. Setti
-
Publication number: 20090018143Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): wherein Ar, X, Y, R1, R2, R3, and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder (“ADHD”), enhancing function in disorders associated with hypofunctionality of the cerebral cortex, including, but not limited to, depression, schizophrenia, fatigue, in particular, fatigue associated with neurologic disease, such as multiple sclerosis, chronic fatigue syndrome, and improvement of cognitive dysfunction.Type: ApplicationFiled: November 8, 2007Publication date: January 15, 2009Applicants: Cephalon, Inc., Cephalon FranceInventors: Brigitte Lesur, Philippe Louvet, Rabindranath Tripathy
-
Publication number: 20090018202Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.Type: ApplicationFiled: February 1, 2005Publication date: January 15, 2009Applicant: Cephalon, Inc.Inventors: Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
-
Patent number: 7476754Abstract: The present invention relates to compounds derived from biphenyl with activity as calpain inhibitors. One compound of the present invention is a 2,2?-disubstituted biphenyl, where the substituents in the 2 and 2? positions of the biphenyl skeleton are chains containing structures related to amino acids, including fragments of aminocarbonylic compounds where at least one of the substituents in said 2- or 2?-positions is bonded to the biphenyl skeleton via a thiocarbonyl group, forming compounds with thioamide functionality. The present invention also encompasses any of the conformational isomers (atropisomers) of said compound of formula I. The compounds of formula I have application in the preventive or therapeutic treatment of a degenerative disease.Type: GrantFiled: May 6, 2005Date of Patent: January 13, 2009Assignee: Consejo Superior de Investigaciones CientificasInventors: Bernardo Herradon Garcia, Mercedes Alonso Giner, Esperanza Benito Cano, Antonio Chana Lopez, Ana Montero Aguado
-
Publication number: 20090012153Abstract: The invention relates to novel compounds of formula (I): H2N—CH(R1)—CH2—S—S—CH2—CH(R2)—CONH—R5, wherein R1 is a hydrocarbon chain, phenyl or benzyl radical, methylene radical substituted by a 5 or 6 atom heterocycle; R2 is a phenyl or benzyl radical, a 5 or 6 atom aromatic heterocycle, methylene group substituted by a 5 or 6 atom heterocycle; R5 is a CH(R3)—COOR4 radical, wherein R3 is hydrogen, an OH or OR group, a saturated hydrocarbon group, a phenyl or benzyl radical and OR4 is hydrophile ester, or 5 or 6 membered heterocycle comprising several heteroatoms selected from a group consisting of nitrogen, sulphur and oxygen, with at least two nitrogene atoms, wherein said heterocycle is substitutable by an alkyl C1-C6, phenyl or benzyl radical.Type: ApplicationFiled: June 26, 2008Publication date: January 8, 2009Applicant: PharmaleadsInventors: Bernard Roques, Marie-Claude Fournie-Zaluski
-
Publication number: 20080319227Abstract: The present invention generally relates to an improved process for preparing modafinil and analogs thereof. The process minimizes impurities and improves the overall yield by oxidizing a modafinil intermediate compound in a reaction mixture including an alcohol and an organic acid at a ratio of from about 1:1 to about 80:1 (by volume).Type: ApplicationFiled: November 27, 2006Publication date: December 25, 2008Inventors: Sidney Liang, John R. Duchek, Carl J. Schaefer
-
Publication number: 20080312329Abstract: Disclosed are selective inhibitors of matrix metalloproteinases represented by the following formula (I). wherein X is (CH2)nO, (CH2)nS, (CH2)nNR1, (CH2)n(CH2), or CH?CH, wherein n=0, 1, or 2; R and R1 are, independently, a substituted or unsubstitued alkyl, alkenyl, alkynyl, aryl, heteroaryl group, cycloalkyl, heterocycloalkyl, cycloalkenyl, or heterocycloalkenyl; and Z is NH or CH2; or a pharmaceutically acceptable salt thereof. Also disclosed are methods of making such compounds and methods of using such compounds to inhibit tumor progression and to treat diseases such as arthritis.Type: ApplicationFiled: March 21, 2005Publication date: December 18, 2008Applicant: SOUTHERN RESEARCH INSTITUTEInventor: Subramaniam Ananthan
-
Publication number: 20080306100Abstract: The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I). The novel compounds of the formula 1 can be used in the therapy of Chronic Myeloid Leukemia (CML). Since the IC50; 191 values of these molecules are in the range 0.1 to 10.0 nm, these novel compounds are potentially useful for the treatment of CML. The present invention relates to a particular form of the (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula I), processes for the preparation thereof, pharmaceutical compositions containing this crystal form, and their use as anti tumor agent in humans.Type: ApplicationFiled: March 4, 2008Publication date: December 11, 2008Applicant: Natco Pharma LimitedInventors: Amala Kishan KOMPELLA, Bhujanga Rao ADIBHATLA KALI SATYA, Sreenivas RACHAKONDA, Nannapaneni VENKAIAH CHOWDARY
-
Publication number: 20080287446Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: ApplicationFiled: March 22, 2006Publication date: November 20, 2008Inventor: Craig J. Mossman
-
Patent number: 7449594Abstract: A process for preparing 4-pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings indicated in the specification. The compounds of formula I are NEH1 inhibitors and can be employed, for example, for the treatment of cardiovascular disorders.Type: GrantFiled: October 6, 2006Date of Patent: November 11, 2008Assignee: Sanofi-aventis Deutschland GmbHInventors: Gerrit Schubert, Heinz-Werner Kleemann
-
Patent number: 7446225Abstract: The invention relates to pentafluorosulfanylphenyl-substituted benzoylguanidines of the formula I: and a process for preparing a compound of the formula I and/or the pharmaceutically acceptable salts thereof.Type: GrantFiled: March 9, 2007Date of Patent: November 4, 2008Assignee: Sanofi-aventis Deutschland GmbHInventor: Heinz-Werner Kleeman
-
Publication number: 20080269283Abstract: Aryl sulfone compounds of formula I and II are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:Type: ApplicationFiled: June 27, 2008Publication date: October 30, 2008Inventors: Pingchen Fan, Hiroyuki Goto, Xiao He, Makoto Kukutani, Marc Labelle, Dustin L. McMinn, Jay P. Powers, Yosup Rew, Daqing Sun, Xuelei Yan
-
Publication number: 20080269282Abstract: This invention is directed to inhibitors of copper-containing amine oxidases (E.C.1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-I), and their therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer.Type: ApplicationFiled: August 2, 2005Publication date: October 30, 2008Applicant: GENMEDICA THERAPEUTICS SLInventors: Luc Marti Clauzel, Silvia Garcia Vicente, Francesc Yraola Font, Miriam Royo Exposito, Fernando Albericio Palomera, Antonio Zorzano Olarte